The goal of treating an individual with epilepsy is to have no seizures and no side effects. Limiting availability of medications appears to be a simple way of controlling costs of patient care. This approach potentially jeopardizes both efficacy and safety. We argue, in this edition of , that limiting costs by restricting formularies is detrimental to the patients from an efficacy, safety, and cost perspective.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613218 | PMC |
http://dx.doi.org/10.1212/CPJ.0b013e318283ff65 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!